Monday, July 25, 2016

Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.

   
News Releases
Aurinia Establishes At-The-Market Facility
July 22, 2016 read more ...

Aurinia Announces Appointment of Head of Communications & Advocacy
July 11, 2016 read more ...

Aurinia Announces 24 Week Remission Rates From the First Seven Patients in ... AURION
June 28, 2016 read more ...

Aurinia Announces Closing of US$7 Million Private Placement
June 22, 2016 read more ...

Aurinia Announces Private Placement
June 15, 2016 read more ...

Aurinia Announces Results of Annual General Meeting
June 9, 2016 read more ...

Aurinia Announces Presentations at the ERA-EDTA Meeting
May 12, 2016 read more ...

Aurinia Reports First Quarter 2016 Financial Results and Operational Highlights
May 11, 2016 read more ...

Aurinia Initiates First Clinical Study of Voclosporin for Japan
May 9, 2016 read more ...

View more news releases
Click here read more ...

 

Lupus Nephritis – Our Core Strategic Focus

Our lead drug, voclosporin, is an immunosuppressant that has utility across many indications. Although voclosporin has been shown to be effective in indications such as prevention of rejection in renal transplantation, it is the lupus market where our company’s key focus now lies.  Kidney Inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis (LN), and it is estimated that approximately 40-50% of all SLE patients have clinical LN requiring treatment. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels.  Poorly controlled LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition.

 

  Voclosporin 






Media Coverage
View more media
Click here read more ...

Home   |   About Aurinia   |   Our Team   |   Products In Development   |   For Investors   |   Partnerships   |   Contact
Copyright 2013 by Aurinia Pharmaceuticals Inc.